T. Gorlia

540 total citations
15 papers, 367 citations indexed

About

T. Gorlia is a scholar working on Genetics, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, T. Gorlia has authored 15 papers receiving a total of 367 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Genetics, 5 papers in Molecular Biology and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in T. Gorlia's work include Glioma Diagnosis and Treatment (8 papers), Brain Metastases and Treatment (3 papers) and Radiomics and Machine Learning in Medical Imaging (2 papers). T. Gorlia is often cited by papers focused on Glioma Diagnosis and Treatment (8 papers), Brain Metastases and Treatment (3 papers) and Radiomics and Machine Learning in Medical Imaging (2 papers). T. Gorlia collaborates with scholars based in Belgium, Netherlands and Germany. T. Gorlia's co-authors include Martin J. van den Bent, Johan Menten, Johan M. Kros, Roger Stupp, Olivier Chinot, M. Frénay, Carin C.D. van der Rijt, Ch.J. Vecht, Alba A. Brandes and Anouk Allgeier and has published in prestigious journals such as Journal of Clinical Oncology, European Journal of Cancer and Neuro-Oncology.

In The Last Decade

T. Gorlia

15 papers receiving 358 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
T. Gorlia Belgium 8 281 161 93 77 71 15 367
J. Curschmann Switzerland 4 331 1.2× 172 1.1× 67 0.7× 57 0.7× 65 0.9× 6 431
Jean-Yves Delattre France 10 240 0.9× 177 1.1× 49 0.5× 34 0.4× 33 0.5× 11 306
Renate Haselmann Germany 7 148 0.5× 212 1.3× 58 0.6× 31 0.4× 43 0.6× 9 352
Despina Misailidou Greece 8 278 1.0× 183 1.1× 92 1.0× 33 0.4× 75 1.1× 9 417
Alessandra Mirri Italy 9 111 0.4× 159 1.0× 30 0.3× 36 0.5× 65 0.9× 15 307
Murali Chintagumpala United States 7 140 0.5× 68 0.4× 63 0.7× 50 0.6× 29 0.4× 14 262
Luc Verbeke Belgium 8 158 0.6× 66 0.4× 77 0.8× 67 0.9× 46 0.6× 19 305
E. Scelzi Italy 6 156 0.6× 75 0.5× 50 0.5× 59 0.8× 44 0.6× 11 311
Aditya Shenoy United Kingdom 9 294 1.0× 169 1.0× 189 2.0× 16 0.2× 127 1.8× 11 515
Deepak Bhamidipati United States 11 109 0.4× 104 0.6× 79 0.8× 26 0.3× 47 0.7× 23 307

Countries citing papers authored by T. Gorlia

Since Specialization
Citations

This map shows the geographic impact of T. Gorlia's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by T. Gorlia with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites T. Gorlia more than expected).

Fields of papers citing papers by T. Gorlia

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by T. Gorlia. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by T. Gorlia. The network helps show where T. Gorlia may publish in the future.

Co-authorship network of co-authors of T. Gorlia

This figure shows the co-authorship network connecting the top 25 collaborators of T. Gorlia. A scholar is included among the top collaborators of T. Gorlia based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with T. Gorlia. T. Gorlia is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Bent, Martin J. van den, Sara Erridge, Michael A. Vogelbaum, et al.. (2019). PL3.3 Second interim and first molecular analysis of the EORTC randomized phase III intergroup CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q codeletion. Neuro-Oncology. 21(Supplement_3). iii3–iii3. 18 indexed citations
2.
Preusser, Matthias, Antonio Silvani, Émilie Le Rhun, et al.. (2019). PL3.2 Trabectedin for recurrent WHO grade II or III meningioma: a randomized phase II study of the EORTC Brain Tumor Group (EORTC-1320-BTG). Neuro-Oncology. 21(Supplement_3). iii2–iii3. 5 indexed citations
3.
Happold, Caroline, T. Gorlia, Olivier Chinot, et al.. (2015). 26LBA Does valproic acid improve survival in glioblastoma? A meta-analysis of randomized trials in newly diagnosed glioblastoma. European Journal of Cancer. 51. S723–S723. 1 indexed citations
4.
Rampling, R., Marc Sanson, T. Gorlia, et al.. (2012). A phase I study of LY317615 (enzastaurin) and temozolomide in patients with gliomas (EORTC trial 26054). Neuro-Oncology. 14(3). 344–350. 14 indexed citations
5.
Rampling, R., Marc Sanson, Walter Taal, et al.. (2009). Phase 1 study of LY317615 (enzastaurin) and temozolomide in patients with gliomas - EORTC trial 26054. Journal of Clinical Oncology. 27(15_suppl). e13005–e13005. 2 indexed citations
6.
7.
Bent, Martin J. van den, R. Rampling, Mathilde C.M. Kouwenhoven, et al.. (2007). Randomized phase II trial of erlotinib (E) versus temozolomide (TMZ) or BCNU in recurrent glioblastoma multiforme (GBM): EORTC 26034. Journal of Clinical Oncology. 25(18_suppl). 2005–2005. 42 indexed citations
8.
Bent, Martin J. van den, R. Rampling, Mathilde C.M. Kouwenhoven, et al.. (2007). 2503 ORAL Erlotinib (E) versus temozolomide (TMZ) or BCNU in recurrent glioblastoma multiforme (GBM): results from a randomized phase II trial (EORTC 26034). European Journal of Cancer Supplements. 5(4). 228–228. 4 indexed citations
9.
10.
Gorlia, T., et al.. (2005). CN2 COST-EFFECTIVENESS OFTEMOZOLOMIDE FORTHE TREATMENT OF NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME IN THE UK. Value in Health. 8(6). A21–A21. 1 indexed citations
11.
Gorlia, T., Roger Stupp, E. Eisenhauer, et al.. (2004). Clinical prognostic factors affecting survival in patients with newly diagnosed Glioblastoma Multiforme (GBM). Journal of Clinical Oncology. 22(14_suppl). 9599–9599. 2 indexed citations
12.
Hegi, Monika E., Marie‐France Hamou, T. Gorlia, et al.. (2004). 31 Temozolomide (TMZ) targets only glioblastoma with a silenced MGMT-gene. Results of a translational companion study to EORTC 26981/NCIC CE.3 of radiotherapy ± TMZ. European Journal of Cancer Supplements. 2(8). 14–14. 3 indexed citations
13.
14.
Bent, Martin J. van den, Alba A. Brandes, Johan Menten, et al.. (2003). Phase II Study of First-Line Chemotherapy With Temozolomide in Recurrent Oligodendroglial Tumors: The European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971. Journal of Clinical Oncology. 21(13). 2525–2528. 223 indexed citations
15.
Neymark, Niels, et al.. (2001). Cost-effectiveness of the addition of early hormonal therapy in locally advanced prostate cancer. European Journal of Cancer. 37(14). 1768–1774. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by J. Curschmann Breakdown of academic impact, for papers by Jean-Yves Delattre Breakdown of academic impact, for papers by Renate Haselmann Breakdown of academic impact, for papers by Despina Misailidou Breakdown of academic impact, for papers by Alessandra Mirri Breakdown of academic impact, for papers by Murali Chintagumpala Breakdown of academic impact, for papers by Luc Verbeke Breakdown of academic impact, for papers by E. Scelzi Breakdown of academic impact, for papers by Aditya Shenoy Breakdown of academic impact, for papers by Deepak Bhamidipati
Rankless by CCL
2026